BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for ...

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) announced upcoming data presentations and programming at ...

The Alzheimer's Society Cymru has responded to the approval of a new Alzheimer's treatment. The Medicines and Healthcare ...

Donanemab, the most effective treatment yet for the disease, has been banned on the health service despite regulators ...

Key Presentations and Symposia: Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from an Alzheimer's Disease ...

Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...

Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for ...

Donanemab has been hailed as 'game changer' but the price tag has barred it from being available to nearly one million Brits.

The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.

A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like ...

Health spending watchdog said costs could not justify benefits after treatment slowed cognitive decline by around four to ...